CryoLife/Medafor
This article was originally published in The Gray Sheet
Executive Summary
CryoLife boosts its equity stake in privately held surgical hemostat maker Medafor to 11% through the purchase of 740,000 shares at $2 each, announced Feb. 2. Surgical adhesive maker CryoLife, which remains Medafor's largest shareholder, is seeking a negotiated acquisition of the rest of Medafor (1"The Gray Sheet" Jan. 18, 2010). While Medafor's board is weighing its options, CryoLife says it may seek a special shareholders meeting to replace the board
You may also be interested in...
CryoLife Takes Step To Wrest Control Of Reluctant Partner Medafor
CryoLife's purchase of an 8% equity stake in privately held surgical hemostat maker Medafor on Jan. 13 could be the first step of a hostile takeover
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.